Exenatide: what the studies show

Immediate and extended release

Exenatide has immediate-release and extended-release products. Byetta's label describes subcutaneous injections twice daily before meals for adults with type 2 diabetes. Bydureon BCise uses an extended-release formulation once weekly, without a meal requirement, for adults and children aged 10 years or older with type 2 diabetes. Both accompany diet and exercise.

FDA's current product records list AstraZeneca's Byetta and Bydureon BCise presentations as discontinued. That marketing status does not mean approval was withdrawn or establish current pharmacy stock.

What the trials found

DURATION-1 randomized 295 adults with type 2 diabetes. Over 30 weeks, weekly extended-release treatment reduced HbA1c more than twice-daily immediate-release treatment. The comparison was open-label and did not test every later device.

EXSCEL studied weekly extended-release exenatide in 14,752 adults. It met the trial's cardiovascular safety comparison with placebo, called noninferiority. It did not show significant superiority. Lower glucose does not prove fewer cardiovascular events.

Record the product and formulation

Record the full brand or generic product name and release formulation. A weekly entry cannot describe immediate-release Byetta. Neither label establishes an obesity indication. The shared molecule name does not establish each product's long-term benefits.